Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Rectal Neoplasms 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms 1Hematologic Neoplasms 1Cardiovascular Diseases 1Advanced Solid Tumor 1

Interventions

Injections 5tislelizumab 4pembrolizumab 4toripalimab 3sotorasib 1serabelisib 1olaparib 1nedaplatin 1mirdametinib 1erdafitinib 1envafolimab 1darolutamide 1atezolizumab 1adagrasib 1abiraterone 1Taxes 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fulvestrant 1Drug Therapy 1CD3 Complex 1Bevacizumab 1Antineoplastic Agents 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × Antineoplastic Agents × 90 days × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡